DAIHAN Scientific Co., Ltd. Overview
DAIHAN Scientific is a Wonju-based, family-controlled small cap that combines two businesses most laboratory-equipment companies keep separate: it manufactures its own DAIHAN-brand general laboratory instruments (ovens, incubators, baths and circulators, stirrers, shakers, furnaces, freezers, autoclaves) and it acts as one of Korea's largest multi-brand distributors of third-party laboratory equipment and consumables to universities, government research institutes, corporate R&D centres, pharmaceutical companies and hospitals. Distribution dominates the revenue mix (about 81% merchandise versus 18% own products in Q2 2026) [S3]. The company has added a medical-device line (Daihan Medical: MFDS-certified ultra-low-temperature vaccine freezers, sterilisers, centrifuges, biosafety cabinets, mediclin™ consumables) and an IoT layer (Smart-Lab controllers, Wire app). Revenue reached KRW 81.1 billion in FY2025 with a 6.8% operating margin, a net-cash balance sheet and a 3–4% dividend yield, yet the shares trade at roughly 0.5x book, reflecting low growth visibility, heavy exposure to Korean public R&D budgets and sizeable minority interests in subsidiaries.
What the company does
DAIHAN Scientific operates as an integrated "total service" supplier to laboratories. Its own long-standing slogan, reproduced by distributor DKSH, is "Customer Oriented Total Service" [S10]. The business has three operating layers:
-
Manufacturing (own products). At its Wonju production campus the company designs and builds general-purpose laboratory instruments under the DAIHAN brand. In 2012 the company stated annual production capacity of about KRW 30 billion and distribution capacity of about KRW 90 billion [S5, 2012]. Own products represented approximately 18% of revenue in Q2 2026 [S3].
-
Distribution (merchandise). The company sources tens of thousands of SKUs from domestic and foreign manufacturers and sells them through direct sales, a national agency (dealer) network and logistics centres. In 2013 it reported about 30,000 products from roughly 170 manufacturers, sold through 45 agencies and 2 logistics centres [S5, 2013]. Later partner-network descriptions range from "about 270" manufacturers (DKSH brand page) to "more than 70 companies in 16 countries and 140 manufacturers in Korea" (KP International) [S10]. Merchandise represented approximately 81% of revenue in Q2 2026 [S3].
-
Services and digital. The company provides installation, after-sales service, equipment rental (cited by its Algerian representative) and IoT-based laboratory monitoring through the DAIHAN Smart-Lab controller and the Wire app and web service for collecting, analysing and sharing experimental data [S9; S10]. A 90%-owned subsidiary, (주)대한랩서비스 (Daihan Lab Service), is consolidated [S1].
Company's own description
DART-derived summaries describe DAIHAN as a manufacturer, distributor and comprehensive service provider of research laboratory equipment and consumables [S9 via Investing.com; S15]. In 2025 press material the company described itself as Korea's first and largest integrated distributor, manufacturer and total-service provider of laboratory and medical equipment [S6].
Business model and revenue model
| Revenue stream | Nature | Approx. share | Source / period |
|---|---|---|---|
| Merchandise (third-party products) | Product resale; distribution margin | 81% | S3, Q2 2026 |
| Products (DAIHAN-manufactured) | Own-brand manufacturing margin | 18% | S3, Q2 2026 |
| Other (services, rental, other) | Service / rental | 1% | S3, Q2 2026 |
| Subscription / licensing | Not reported as a separate stream; Wire app and Smart-Lab are bundled with hardware as far as disclosed | 0 | — |
The model is overwhelmingly transactional product revenue. There is no disclosed recurring subscription or licensing revenue. Consumables (glassware, plasticware, mediclin™ medical consumables) provide some repeat purchasing; in 2013 glassware such as beakers and flasks was cited as only about 5% of sales [S5, 2013].
Value-chain position
DAIHAN sits at two points of the laboratory-equipment value chain simultaneously: as an OEM-brand manufacturer of mid-technology "general lab" instruments (temperature control, mixing, sterilisation), and as a channel intermediary between global or domestic instrument makers and Korean end users. Its distribution role gives it procurement relationships across most Korean public research institutions, which in turn creates a captive channel for its own-brand instruments.
Customer types and end-markets
| Customer type | Examples of demand | Source |
|---|---|---|
| Government organisations and public research institutes | National R&D programmes; equipment procurement via public tender | S9 (Morningstar); S1 |
| Universities | Teaching and research laboratories | S9; S7 |
| Corporate R&D centres | Bio/nano materials, refining and chemicals, electrical/electronics/semiconductor research | S5, 2013 |
| Pharmaceutical companies | QC and R&D laboratories | S9 |
| Hospitals and clinics | Vaccine/blood freezers, sterilisers, centrifuges, biosafety cabinets | S6 |
| Overseas distributors and institutional buyers | Vietnam, Indonesia, Egypt (military hospital tender), Europe | S6; S8 |
Independent characterisation
DAIHAN is best characterised as a domestic, budget-driven laboratory-supply distributor with a captive manufacturing arm. Revenue tracks Korean public and private R&D spending with a short lag (illustrated by the 2.7% revenue decline in FY2024, when the national R&D budget was cut to KRW 26.5 trillion, and the 13.1% rebound in FY2025 as the budget recovered to KRW 29.6 trillion) [S1; S11]. Gross margins in the high-20s percent reflect the distribution-heavy mix; operating margins have ranged from 3.6% to 10.0% over the past decade [S1]. The consolidated group includes several partially-owned sales subsidiaries, so a material share of consolidated profit (about 31% in FY2025) accrues to minority shareholders [S2].
Strategy
DAIHAN does not publish an investor-day presentation, medium-term plan or Corporate Value-Up Plan in the sources reviewed (contrast: peer Seoulin Bioscience filed a voluntary value-up plan on 21 Apr 2026 [S14]). Strategic themes below are drawn from company press statements and observed actions.
Stated strategic themes (paraphrased)
-
"Customer Oriented Total Service" — one-stop procurement, manufacturing and service for laboratories [S10].
-
Global DAIHAN — building an overseas subsidiary/franchise and distributor network to sell own-brand instruments worldwide (articulated 2015; continued via Vietnam, Indonesia, Egypt, MEDICA) [S8; S6].
-
From lab-equipment leader to medical-device player — expanding GMP-certified medical devices and partnering with domestic and foreign specialists to broaden the medical line; building brand power in medical devices [S6].
-
Smart laboratory / IoT — Smart-Lab System, Wire app, IoT-enabled cold chain [S8; S9; S6].
-
Eco-friendly refrigeration — in-house refrigerant DH-MGR in freezers and refrigerators [S6].
Initiatives in the last 24 months
| Date | Initiative | Type | Source |
|---|---|---|---|
| 2,024 | Indonesian distributor appointed (via KIMES 2024) | Channel expansion | S6 |
| Mar 2025 | KIMES 2025 participation; GMP-certified devices showcased | Medical-device marketing | S6 |
| Mar 2025 | Egyptian military hospital ULT freezer tender win (6 units) | Export | S6 |
| Jun 2025 | Industry–academia cooperation agreement with Sangji University | Partnership / talent | S7 |
| Jul 2025 | Digital-healthcare social-contribution alliance MOU with Sangji University | ESG / partnership | S7 |
| Jul–Dec 2025 | Planned participation (directly or via distributors) at Medipharm Expo HCMC (Jul), Indonesia Hospital Expo (Oct), MEDICA Düsseldorf (Nov), Medipharm Expo Hanoi (Dec) | Export marketing | S6 |
| Oct 2025 | Equipment donation (fume hood and two other items, KRW 27.2 M) to Sangji University | ESG | S7 |
| Feb 2026 | Dividend more than doubled to KRW 125 | Capital return | S1 |
Cost programmes, transformation programmes, sustainability commitments with targets: none disclosed.
Guidance and medium-term targets
Management has not published revenue, margin or return targets in any source reviewed. No earnings guidance is provided.
Products & Services
Pricing is not publicly disclosed for any line; DAIHAN sells through quotation, public tender and distributor price lists. Launch years are not disclosed for most models. Specifications below are those published by DAIHAN's distributors or in company press material.
DAIHAN-manufactured laboratory instruments (Products, ~18% of revenue)
| Product line | Named models / brands | Description and key capabilities | Target customer | Source |
|---|---|---|---|---|
| Programmable tube furnaces | FT-series | Embedded heating-element tube furnaces, maximum 1,000°C, digital PID programmable control | Materials, chemistry and battery research labs | S10 (DKSH) |
| Box/muffle furnaces | Furnace range | High-temperature ashing and heat treatment | Materials, environmental labs | S9 |
| Refrigerated/heating bath circulators | MaXircu™ CL | Digital precise refrigerated and heating bath circulation | Chemistry, biology, QC labs | S10 |
| Chillers / cooling circulators | MaXircu™ Chi | Recirculating chiller for rotary evaporators, reactors and instruments | Chemistry, pharma labs | S10 |
| Water and oil baths | Digital high-temperature oil bath; water baths | Constant-temperature immersion baths | General labs | S10; S9 |
| Laboratory freezers | WLF | Digital laboratory freezer, −35°C to +10°C, 420 L, with certificate | Biology, pharma, hospitals | S10 |
| Ultra-low-temperature freezers | ULT freezer (medical-certified variant) | Vaccine, medicine and blood storage; MFDS medical certification (company-described as a Korean first); uses in-house eco-refrigerant DH-MGR; Smart-Lab IoT monitoring | Hospitals, vaccine programmes, biobanks | S6 |
| Medical refrigerators | Vaccine/pharmaceutical refrigerators | Cold-chain storage for vaccines and drugs | Hospitals, clinics | S6 |
| Drying and heating ovens | Hi-Clean air ovens; forced-convection and natural-convection ovens | Drying, curing, sterilising; clean-air variants | General and semiconductor/electronics labs | S10; S9 |
| Incubators | Incubator range (incl. CO2/BOD types as catalogued) | Microbiology and cell-culture incubation | Life-science labs | S10; S9 |
| Hotplates and hotplate stirrers | Analog and digital hotplate stirrers | Heating plus magnetic stirring | All chemistry/biology labs | S10 |
| Magnetic stirrers | Magnetic stirrer range | Mixing of chemical, laboratory and pharmaceutical materials | General labs | S10 |
| Overhead stirrers | HS-D | High-speed digital overhead stirrer, up to 10/20 L, 200–3,000 rpm, digital feedback control | Chemistry, process development | S10 (KP International) |
| Shakers and vortex mixers | Orbital/reciprocal shakers; vortex mixers | Sample agitation | Biology, chemistry labs | S9 |
| Homogenizers | Homogenizer range | Sample homogenisation and dispersion | Biology, food, pharma labs | S10 |
| Heating mantles | Heating mantle range | Flask heating | Chemistry teaching and research | S9 |
| Heating blocks / dry bath incubators | Dry-bath range | Tube heating | Molecular biology | S9 |
| Autoclaves / sterilisers | Steam autoclaves; dry-heat sterilisers; low-temperature plasma sterilisers | Laboratory and medical sterilisation; multiple capacities including small-clinic sizes | Labs, hospitals, clinics | S6; S9 |
| Centrifuges | Clinical, general-purpose, high-speed refrigerated and micro-haematocrit centrifuges | Micro- and macro-tube rotors | Hospitals, research | S6; S9 |
| Biological safety cabinets | BSC range | Operator and sample protection for infectious-agent work | Hospitals, virology labs | S6 |
| Fume hoods and reagent storage | Fume hoods; filtering reagent cabinets; safety cabinets for corrosive/flammable reagents | Laboratory safety and chemical storage | All labs; universities | S6; S7 |
| Desiccator cabinets | Desiccator range | Moisture-free storage | General labs | S9 |
| Ultrasonic cleaners | Ultrasonic cleaner range (CE certified) | Removal of dirt, grease, waxes and oil from lab ware | General labs | S10 |
| Evaporators and reactors | Evaporator and reactor range | Solvent evaporation, synthesis | Chemistry, pharma | S9 |
| Freeze-dry systems | Freeze-dryer range | Lyophilisation | Pharma, food, biology | S9 |
| Glass/labware washers | Labware washer range | Automated washing | Larger labs | S9 |
| Water purification | Water purification products | Lab-grade water | All labs | S9 |
| Balances and moisture analysers | Analytical balance; moisture analyser | Weighing and moisture determination | QC, general labs | S10 |
| Mills, viscometers, magnifiers, gel documentation | Various | Sample preparation and analysis | General labs | S9 |
Brand architecture: Investing.com describes smart-lab and touch-screen systems sold under the "Wisd" brand [S9]; DAIHAN catalogues have historically used "Wise"-prefixed product family names (for example for stirrers, thermal equipment and circulators).
Digital / smart-laboratory offerings
| Offering | Description | Launch | Source |
|---|---|---|---|
| DAIHAN Smart-Lab System / controller | Instrument controller with experiment data recording, storage management and self-diagnostics; mobile remote control | First shown at ACHEMA 2012 | S8; S9 |
| Wire app and web service | Collection, analysis and sharing of experimental data from connected instruments | — | S9 |
| IoT-enabled cold chain | Smart-Lab monitoring applied to medical freezers and refrigerators | — | S6 |
Daihan Medical (medical devices and consumables)
| Product | Description | Regulatory status | Source |
|---|---|---|---|
| Ultra-low freezers for vaccines/medicines/blood | Eco-refrigerant DH-MGR; IoT monitoring | MFDS medical certification | S6 |
| Medical refrigerators | Vaccine and drug storage | Not specified | S6 |
| Sterilisers (dry heat, high-pressure steam, low-temperature plasma) | Multiple capacities for hospitals and small clinics | GMP-certified devices exhibited | S6 |
| Centrifuges (clinical, high-speed refrigerated, micro-haematocrit) | Micro/macro tubes | GMP-certified devices exhibited | S6 |
| Biosafety cabinets, fume hoods, filtering reagent cabinets, safety cabinets | Laboratory safety for medical research | Not specified | S6 |
| mediclin™ sample containers | Korean-made PP containers, sterile and non-sterile | Not specified | S6 |
| mediclin™ slide glass and cover glass | Microscopy consumables | CE certified | S6 |
| Stainless-steel instruments | Medical and laboratory instruments | Not specified | S6 |
The company stated in March 2025 that Daihan Medical Division revenue was growing strongly each year, but no figures were disclosed [S6].
Distributed third-party merchandise (~81% of revenue)
DAIHAN's distribution catalogue spans general lab equipment, analytical instruments, plasticware, glassware, chemicals-adjacent consumables and safety products from domestic and international manufacturers. Specific principal brands and exclusive distributorships are not named in the sources reviewed. The company referenced supply and alliance agreements with advanced North American and European lab-equipment makers in FY2011 [S5].
Services
| Service | Description | Source |
|---|---|---|
| Total service (installation, after-sales) | Integrated procurement-to-service offering for labs | S10; S6 |
| Equipment rental | Cited by overseas representative | S10 |
| Laboratory services | Via 90%-owned Daihan Lab Service | S1 |
Financial Narrative
All figures K-IFRS consolidated, KRW billion unless noted. Primary sources: S1 (DART business reports compiled by ETF Shopping) for FY2021–FY2025 income-statement totals, EPS and dividends; S2 (Valueline) for FY2022–FY2025 balance sheet and FY2025 line items.
Income statement
Notes: (1) FY2025 EBITDA (KRW 7.16 billion), pre-tax income (KRW 5.65 billion), tax (KRW 0.88 billion), controlling and NCI net income are from S2. (2) EPS discrepancy: S1 reports FY2025 basic EPS of KRW 478; S2 reports KRW 440. S2's controlling net income of KRW 3.28 billion divided by ~7.45 million issued shares implies ~KRW 440; dividing by ~7.2 million outstanding (ex-treasury) shares implies ~KRW 455. The DART figure should be checked directly. (3) Diluted EPS: no dilutive instruments were identified (no convertible bonds or warrants on the balance sheet per S2), so diluted EPS is expected to equal basic EPS; not separately confirmed.
Revenue CAGR: FY2021–FY2025: 5.2% per year (KRW 66.3 billion to 81.1 billion). FY2016–FY2025: 6.5% per year (KRW 46.1 billion to 81.1 billion) [S1].
Ten-year revenue and operating income context
Source: S1, DART business reports FY2016–FY2025: ### Quarterly trajectory
Source: S1, DART quarterly/half-year/business reports, filed 16 May 2024 to 14 Aug 2026.
H1 2026 summary: revenue KRW 39.2 billion (+13.0% vs. KRW 34.7 billion in H1 2025); operating income KRW 3.1 billion (+19% vs. KRW 2.6 billion); net income KRW 2.8 billion (vs. KRW 2.2 billion) [S1, analyst aggregation of quarterly figures]. Trailing-twelve-month revenue to June 2026: KRW 85.6 billion; TTM operating income KRW 5.95 billion; TTM EBITDA KRW 7.71 billion [S2].
Balance sheet
Sources: S2 (FY2022–FY2025 line items); S1 (FY2021 cash and total liabilities). Total borrowings exclude "short-term financial liabilities" of KRW 3.8 billion (FY2025), whose composition (likely lease and other financial liabilities) is not detailed in S2.
Balance sheet at 30 June 2026: total assets KRW 73.1 billion; cash KRW 3.4 billion; short-term financial assets KRW 12.5 billion; inventories KRW 28.2 billion (merchandise KRW 15.4 billion, products KRW 5.9 billion, raw materials KRW 5.1 billion); trade receivables KRW 8.1 billion; borrowings nil; total liabilities KRW 14.7 billion; equity attributable to owners KRW 46.1 billion; NCI KRW 12.4 billion; total equity KRW 58.4 billion; BVPS KRW 6,180.
Revaluation: a land revaluation surplus rose from KRW 2.26 billion (FY2023) to KRW 3.89 billion (FY2024), coinciding with land carrying value rising from KRW 6.09 billion to KRW 8.15 billion; FY2024 other comprehensive income included a KRW 1.63 billion revaluation gain [S2]. This flatters FY2024 equity growth relative to retained earnings.
Cash flow
Sources: S2 for FY2025 cash-flow items (OCF KRW 5.44 billion; PP&E purchases KRW 0.31 billion; D&A KRW 1.77 billion; consolidated dividends paid KRW 0.69 billion; LTD repayment KRW 1.20 billion); S1 for dividends declared and treasury purchases FY2021–FY2025. S1 reports FY2025 FCF of KRW 5.1 billion; S2 reports KRW 5.21 billion on its own definition.
Trailing twelve months to June 2026: OCF KRW 5.20 billion; PP&E purchases KRW 0.47 billion; FCF KRW 4.30 billion; consolidated dividends paid KRW 1.31 billion (reflecting the higher FY2025 dividend paid in April 2026).
Ratios
All ratios are analyst calculations from S1/S2 data using closing balances. ROIC uses an FY2025 effective tax rate of 15.6% (tax KRW 0.88 billion / pre-tax KRW 5.65 billion). Third-party published ratios: S1 reports ROE 8.4%, ROA 6.6%, payout 26–28%; S2 reports TTM ROE 7.75%.
Commentary on trends, inflections and drivers
Revenue. DAIHAN has compounded revenue at roughly 5–7% per year for a decade, with only two down years (FY2017, −10.2%; FY2024, −2.7%) [S1]. The FY2024 contraction coincided precisely with the Korean government's 2024 R&D budget cut to KRW 26.5 trillion (down from KRW 29.3 trillion-plus in 2023 per Newsis's 9.4% decline figure) [S11]. The FY2025 rebound of 13.1% to a record KRW 81.1 billion, and continued 12–14% quarterly growth through Q2 2026, track the partial restoration of the budget to KRW 29.6 trillion in 2025 and its further expansion to roughly KRW 35.3–35.5 trillion for 2026 [S1; S11]. The company's own statements also point to growth in the Daihan Medical division and export orders [S6].
Margins. Gross margin peaked at 30.1% in FY2023 and has since settled at 27.7% for two years [S1]. The FY2024 compression was primarily operating deleverage: gross profit fell KRW 2.3 billion on flat SG&A. In FY2025, gross profit recovered but SG&A rose 7.6% to KRW 16.9 billion, so operating margin only partially recovered to 6.8%, still well below the FY2022 peak of 10.0%. Personnel costs are a growing burden: standalone payroll reached KRW 5.93 billion (12.6% of standalone revenue) in FY2025, up from 10.9% in FY2021, with average pay rising 16.6% between FY2021 and FY2025 [S1]. Foreign-exchange losses (KRW 0.73 billion) exceeded FX gains (KRW 0.47 billion) in FY2025 [S2], consistent with the import-heavy merchandise mix.
Quarterly volatility. Q4 is the largest revenue quarter (year-end public procurement), but Q4 2025 operating profit fell 54% YoY to KRW 0.6 billion on record revenue of KRW 25.2 billion [S1]. The cause is not disclosed in the sources reviewed; possibilities include year-end bonus accruals, inventory write-downs or a lower-margin project mix. This is a key monitorable.
Minority leakage. About 31% of FY2025 consolidated net income (KRW 1.49 billion of KRW 4.77 billion) belonged to non-controlling shareholders of subsidiaries [S2]. Valuation multiples should therefore be measured on owners' earnings and owners' equity.
Balance sheet. The company is effectively debt-free (KRW 0.2 billion borrowings at FY2025; nil at June 2026) with KRW 16.1 billion of cash and short-term financial instruments at FY2025 [S2]. Net cash has more than doubled since FY2022. However, inventory is the largest asset (35% of total assets at FY2025) and rose a further 11% to KRW 28.2 billion in H1 2026, while cash fell to KRW 3.4 billion at June 2026, partly reflecting the doubled dividend paid in April [S2].
Working capital and cash conversion. The cash conversion cycle is long at ~169 days, driven by ~158 days of inventory [analyst calculation from S2]. DSO lengthened from 29 to 40 days between FY2022 and FY2025 as receivables jumped 38% in FY2025 on Q4 revenue concentration. FY2025 OCF of KRW 5.4 billion nonetheless exceeded net income, helped by D&A of KRW 1.8 billion and minimal capex (KRW 0.3 billion), giving a FCF yield of roughly 20% on market capitalisation.
Capital returns. DPS was flat at KRW 60 for seven years (FY2018–FY2024) before more than doubling to KRW 125 for FY2025 [S1]. Treasury purchases of KRW 0.5–1.0 billion were made in 2018, 2020, 2022, 2023 and 2024 but none in 2025 [S1]. Total shareholder returns in FY2025 were about 28% of owners' net income [S1].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue type
| Revenue type | Contents | Share of revenue (%) Q2 2026 | Source |
|---|---|---|---|
Merchandise (상품) | Third-party lab equipment, analytical instruments, consumables, medical supplies | 81 | S3 |
Products (제품) | DAIHAN-manufactured instruments (temperature control, mixing, sterilisation, freezers, safety cabinets) | 18 | S3 |
Other (기타) | Services, rental, other | 1 | S3 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 73.7 | 71.7 | 81.1 |
Total revenue YoY growth (%) | 2.0 | -2.7 | 13.1 |
Revenue by Segment
| Metric | FY2025 |
|---|---|
Consolidated revenue (KRW Bn) | 81.1 |
Standalone (parent) revenue (KRW Bn) | 47.0 |
Implied subsidiary contribution before eliminations (KRW Bn) | 34.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | DAIHAN stake (%) | Total assets (KRW Bn) | Net income (KRW Bn) | Inferred role | Source / period |
|---|---|---|---|---|---|
DAIHAN VIETNAM CO., LTD. | 50.06 | 4.0 | 0.25 | Vietnam sales/distribution | S1, latest FY |
(주)싸이랩코리아 (Sci-Lab Korea) | 37.78 | 17.3 | 1.48 | Domestic lab-supply affiliate; also holds 7.95% of DAIHAN | S1, latest FY |
(주)올포랩 (AllforLab) | 73.5 | 3.42 | 0.17 | Domestic lab-supply sales | S1, latest FY |
(주)대한과학대구경북지사 (DAIHAN Daegu-Gyeongbuk branch company) | 50.2 | 4.31 | 0.62 | Regional sales company | S1, latest FY |
(주)대한랩서비스 (Daihan Lab Service) | 90.0 | 0.24 | 0.025 | Laboratory services | S1, latest FY |
㈜올랩 (Allab) | 50.5 | 1.44 | 0.27 | Domestic sales | S1, latest FY |
(주)대한분석기기 (Daihan Analytical Instruments) | 51.0 | 0.24 | 0.003 | Analytical-instrument sales | S1, latest FY |
DAIHAN Scientific Europe B.V. | — | — | — | European franchise entity (established 2015); current status not confirmed | S8 |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 66.3 | 72.3 | 73.7 | 71.7 | 81.1 |
Revenue growth (%) | 7.8 | 9.1 | 2.0 | -2.7 | 13.1 |
Cost of sales (KRW Bn) | 47.8 | 50.7 | 51.5 | 51.8 | 58.7 |
Gross profit (KRW Bn) | 18.4 | 21.6 | 22.2 | 19.9 | 22.5 |
SG&A (KRW Bn, gross profit minus operating income) | 12.5 | 14.4 | 16.0 | 15.7 | 16.9 |
Operating income (KRW Bn) | 5.9 | 7.2 | 6.2 | 4.2 | 5.5 |
EBITDA (KRW Bn) | — | — | — | — | 7.2 |
Pre-tax income (KRW Bn) | — | — | — | — | 5.7 |
Income tax (KRW Bn) | — | — | — | — | 0.9 |
Net income, total (KRW Bn) | 5.0 | 6.2 | 5.2 | 3.9 | 4.8 |
Net income attributable to owners (KRW Bn) | — | — | — | — | 3.3 |
Net income attributable to NCI (KRW Bn) | — | — | — | — | 1.5 |
EPS basic (KRW, S1) | 524 | 657 | 543 | 386 | 478 |
Dividend per share (KRW) | 60 | 60 | 60 | 60 | 125 |
Gross margin (%) | 27.8 | 29.8 | 30.1 | 27.7 | 27.7 |
Operating margin (%) | 8.8 | 10.0 | 8.4 | 5.9 | 6.8 |
EBITDA margin (%) | — | — | — | — | 8.8 |
Net margin (%) | 7.6 | 8.6 | 7.1 | 5.5 | 5.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2016–FY2025)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 46.1 | 41.4 | 47.1 | 55.2 | 61.5 | 66.3 | 72.3 | 73.7 | 71.7 | 81.1 |
Operating income (KRW Bn) | 1.6 | 1.9 | 2.6 | 2.2 | 3.6 | 5.9 | 7.2 | 6.2 | 4.2 | 5.5 |
Net income (KRW Bn) | 2.2 | 1.3 | 2.5 | 1.9 | 2.8 | 5.0 | 6.2 | 5.2 | 3.9 | 4.8 |
Operating margin (%) | 3.6 | 4.7 | 5.5 | 4.0 | 5.9 | 8.8 | 10.0 | 8.4 | 5.9 | 6.8 |
EPS (KRW) | 255 | 142 | 242 | 165 | 229 | 524 | 657 | 543 | 386 | 478 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 13.9 | 17.6 | 18.4 | 21.7 | 15.7 | 19.0 | 21.2 | 25.2 | 17.6 | 21.6 |
Operating income (KRW Bn) | 0.8 | 0.9 | 1.2 | 1.3 | 0.9 | 1.7 | 2.3 | 0.6 | 1.0 | 2.1 |
Net income (KRW Bn) | 0.8 | 0.9 | 1.2 | 1.1 | 0.8 | 1.4 | 2.4 | 0.2 | 0.9 | 1.9 |
Revenue YoY (%) | — | — | — | — | 12.9 | 7.9 | 15.0 | 16.0 | 12.1 | 13.8 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | — | 59.5 | 64.0 | 67.8 | 72.2 |
Current assets (KRW Bn) | — | 39.0 | 44.4 | 47.0 | 52.8 |
Cash and cash equivalents (KRW Bn) | 5.7 | 5.1 | 5.7 | 5.4 | 5.0 |
Short-term financial instruments (KRW Bn) | — | 5.1 | 7.1 | 8.0 | 11.1 |
Trade receivables (KRW Bn) | — | 5.8 | 6.3 | 6.5 | 9.0 |
Inventories (KRW Bn) | — | 21.5 | 23.4 | 25.2 | 25.4 |
Property, plant and equipment (KRW Bn) | — | 18.5 | 17.8 | 19.0 | 17.9 |
Goodwill (KRW Bn) | — | 0.0 | 0.0 | 0.0 | 0.0 |
Other intangibles (KRW Bn) | — | 0.3 | 0.2 | 0.2 | 0.1 |
Short-term borrowings incl. current portion of LTD (KRW Bn) | — | 0.1 | 2.5 | 1.5 | 0.2 |
Long-term borrowings (KRW Bn) | — | 2.5 | 0.0 | 0.0 | 0.0 |
Total borrowings (KRW Bn) | — | 2.6 | 2.5 | 1.5 | 0.2 |
Net debt, borrowings less cash and ST financial instruments (KRW Bn) | — | -7.5 | -10.3 | -11.8 | -15.9 |
Total liabilities (KRW Bn) | 16.0 | 15.0 | 15.3 | 14.9 | 15.4 |
Equity attributable to owners (KRW Bn) | — | 36.4 | 39.2 | 42.2 | 45.0 |
Non-controlling interests (KRW Bn) | — | 8.0 | 9.5 | 10.7 | 11.8 |
Total equity (KRW Bn) | — | 44.4 | 48.7 | 52.9 | 56.8 |
Working capital (KRW Bn) | — | 27.0 | 29.7 | 33.3 | 38.5 |
Book value per share (KRW) | — | 4,887 | 5,258 | 5,664 | 6,033 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | — | — | — | — | 5.4 |
Capital expenditure, PP&E and intangibles (KRW Bn) | — | — | — | — | 0.3 |
Free cash flow (KRW Bn) | — | — | — | — | 5.1 |
Depreciation and amortisation (KRW Bn) | — | — | — | — | 1.8 |
Dividends declared by parent (KRW Bn) | 0.4 | 0.4 | 0.4 | 0.4 | 0.9 |
Dividends paid, consolidated incl. to NCI (KRW Bn) | — | — | — | — | 0.7 |
Treasury share purchases (KRW Bn) | 0.0 | 0.5 | 0.5 | 1.0 | 0.0 |
Repayment of long-term borrowings (KRW Bn) | — | — | — | — | 1.2 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, total NI / closing total equity (%) | 14.0 | 10.7 | 7.4 | 8.4 |
ROE, owners' NI / closing owners' equity (%) | — | — | — | 7.3 |
ROA, total NI / closing total assets (%) | 10.4 | 8.1 | 5.8 | 6.6 |
ROIC, NOPAT / (equity + debt − cash and ST investments) (%) | — | — | — | 11.4 |
Current ratio (x) | 3.27 | 3.02 | 3.43 | 3.68 |
Total borrowings / total equity (%) | 5.9 | 5.1 | 2.9 | 0.3 |
Total liabilities / total equity (%) | 33.8 | 31.4 | 28.2 | 27.2 |
Net debt / EBITDA (x) | — | — | — | -2.2 |
Interest coverage, EBIT / interest expense (x) | — | — | — | 138 |
Asset turnover, revenue / closing assets (x) | 1.22 | 1.15 | 1.06 | 1.12 |
Days sales outstanding | 29.4 | 31.2 | 33.0 | 40.4 |
Days inventory outstanding | 154.4 | 166.1 | 177.6 | 157.9 |
Days payables outstanding | 34.8 | 37.0 | 32.4 | 29.6 |
Cash conversion cycle (days) | 149.0 | 160.3 | 178.2 | 168.7 |
Dividend payout, parent dividends / owners' NI (%) | — | — | — | 27 |
Revenue by Region and Revenue by Region (%)
| Region | FY2025 | TTM Jun 2025 | TTM Sep 2025 | TTM Mar 2026 | TTM Jun 2026 |
|---|---|---|---|---|---|
Domestic revenue (KRW Bn) | 72.3 | 66.9 | 68.4 | 74.2 | 76.3 |
Export revenue (KRW Bn) | 8.8 | 8.0 | 9.2 | 8.8 | 9.4 |
Total revenue (KRW Bn) | 81.1 | 74.9 | 77.6 | 83.0 | 85.6 |
Export share (%) | 10.9 | 10.7 | 11.9 | 10.6 | 10.9 |
Country / Region Details
| Country / region | Evidence of activity | Source |
|---|---|---|
Republic of Korea | ~89% of revenue; national agency network | S2; S5 |
Vietnam | 50.06%-owned subsidiary DAIHAN VIETNAM; Vietnamese distributor exhibiting at Medipharm Expo (Ho Chi Minh City, Jul 2025); company participation planned at Medipharm Expo Hanoi (Dec 2025) | S1; S6 |
Indonesia | Distributor agreement signed via KIMES 2024; distributor exhibiting at Indonesia Hospital Expo, Jakarta (Oct 2025) | S6 |
Egypt | Tender win: six ultra-low freezers for a military hospital (reported Mar 2025) | S6 |
Germany / Europe | MEDICA Düsseldorf participation planned (Nov 2025); DAIHAN Scientific Europe B.V. (2015); ACHEMA exhibitor 2012 and 2015 | S6; S8 |
Algeria | Represented by SARL KP International | S10 |
Southeast Asia (DKSH territories) | DAIHAN brand catalogued by DKSH Technology | S10 |
US, China, Turkey, Malaysia | Overseas subsidiaries/franchise entities cited in 2015 | S8 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 6,840 | 6,280 | 4,630 | 4,810 |
Year-end market cap (KRW Bn) | 51.0 | 46.8 | 34.5 | 35.9 |
P/E on year-end price (x) | — | — | — | 10.9 |
P/B on owners' equity (x) | — | 1.19 | 0.82 | 0.80 |
Performance Window to 20 Oct 2026 Details
| Performance window to 20 Oct 2026 (price KRW 3,430) | Return (%) | Source |
|---|---|---|
1 month | -4.2 | S1 |
6 months | -28.4 | S1 |
Year to date (vs. KRW 4,810 at end-2025) | -28.7 | Analyst calc. from S2 |
1 year | -28.5 | S1 |
Since end-2023 (~2.8 years) | -45.4 | Analyst calc. from S2 |
Since end-2022 (~3.8 years) | -49.9 | Analyst calc. from S2 |
Valuation Multiples
| Multiple | DAIHAN | Basis | Seoulin Bioscience | Source |
|---|---|---|---|---|
P/E (TTM) | 7.2x | Price / TTM EPS | 44.95x | S1; S2; S14 |
P/B | 0.56x (owners' equity) / 0.45x (S1 basis) | Jun 2026 equity | 0.49x | S2; S1; S14 |
EV/Sales (TTM) | 0.26x | EV KRW ~22.0 B incl. NCI, less cash and ST investments | — | Analyst calc. from S2 |
EV/EBITDA (TTM) | 2.9x | TTM EBITDA KRW 7.71 B | — | Analyst calc. from S2 |
Price / FCF (FY2025) | ~5.0x | FCF KRW 5.1 B | — | S1 |
Dividend yield | 3.61% | FY2025 DPS KRW 125 | 2.26% | S1; S14 |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Dividend per share (KRW) | 40 | 50 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 125 |
Total dividends declared (KRW Bn) | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.9 |
Treasury purchases (KRW Bn) | 0.0 | 0.0 | 1.0 | 0.0 | 0.3 | 0.0 | 0.5 | 0.5 | 1.0 | 0.0 |
Total shareholder return / NI (%) | 13 | 35 | 81 | 36 | 44 | 12 | 20 | 25 | 54 | 28 |
Capital Markets
| Item | Status | Source |
|---|---|---|
Moody's / S&P / Fitch | Not rated | — |
Domestic ratings (KIS, NICE, Korea Ratings) | No public bond ratings identified (company has no bonds outstanding) | S2 |
Debt maturity profile | No borrowings at 30 Jun 2026; KRW 1.2 B long-term loan repaid in FY2025 | S2 |
Analyst Conclusions
Management guidance
None published.
Growth expectations
No consensus exists. As a reference point, the H1 2026 run-rate (revenue +13.0% YoY) and a national R&D budget up ~19% for 2026 imply FY2026 revenue growth in the low-teens if H2 follows H1; at a flat 6.8% operating margin this would equate to FY2026 revenue of roughly KRW 91–92 B and operating income of about KRW 6.2 B. This is an illustrative analyst scenario, not a forecast or company guidance.
Bull case
-
Budget-driven volume tailwind. The 2026 R&D budget of KRW 35.3–35.5 T is ~33% above the 2024 trough; DAIHAN's revenue has historically moved with budgets (−2.7% in FY2024, +13.1% in FY2025, +13% in H1 2026) [S1; S11].
-
Deep value with downside protection. At ~0.5x book, ~2.9x EV/EBITDA and ~5x price/FCF, the market prices DAIHAN as ex-growth despite record revenue; net cash and short-term investments of KRW 16.0 B at June 2026 equal ~62% of market cap [S2; S1].
-
Capital-return and governance optionality. The doubled dividend, rising insider stake and Korea's value-up / dividend-tax reforms could drive re-rating, particularly if the company simplifies its subsidiary structure or raises payout further [S1; S4].
Bear case
-
Margin ceiling. Despite record revenue, FY2025 operating margin (6.8%) remained well below FY2022 (10.0%); Q4 2025 operating profit fell 54% on record sales, and wage and FX pressures persist [S1; S2].
-
Working-capital drag and cash decline. Inventory rose to KRW 28.2 B and cash fell to KRW 3.4 B by June 2026; a ~169-day cash conversion cycle consumes much of the growth in profit [S2].
-
Structural value leakage. ~31% of consolidated profit goes to minority holders in subsidiaries; reciprocal shareholding with Sci-Lab Korea and family control limit the likelihood of minority-friendly restructuring; no analyst coverage or IR limits rerating catalysts [S1; S2; S15].
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable | Why it matters |
|---|---|---|
| ~Mid-Nov 2026 | Q3 2026 quarterly report | Confirms whether 12–14% growth and operating leverage persist |
| Dec 2026 | National Assembly approval of 2027 R&D budget | Sets FY2027 demand |
| ~Feb 2027 | FY2026 dividend decision | Tests whether KRW 125 DPS is a new floor |
| ~Mar 2027 | FY2026 business report; Q4 margin | Q4 profitability was weak in FY2025 |
| Mar 2027 | KIMES 2027 participation; medical export orders | Evidence of medical-device scale-up |
| Ongoing | Inventory and cash levels | Working-capital discipline |
| Ongoing | Identity and purpose of 2026 large-shareholding filings | Potential control or activism signal |
| Ongoing | Any value-up plan, treasury-share cancellation or subsidiary restructuring | Re-rating triggers |
Analyst verdict
DAIHAN Scientific is a sound but unremarkable business trading at a remarkable discount. Operationally, the company has done what its model allows: it compounded revenue at about 6.5% per year over FY2016–FY2025, kept the balance sheet debt-free, and responded to the 2025–2026 restoration of Korea's national R&D budget with five consecutive quarters of double-digit revenue growth, culminating in a record KRW 81.1 billion in FY2025 and a further 13% increase in H1 2026. The dual manufacturer-distributor structure, a broad supplier network and medical certifications give it a defensible niche in Korea's general-laboratory market.
The constraints are equally clear. Distribution economics cap gross margin in the high-20s percent; R&D at ~1.4% of revenue limits product differentiation against global brands; and a long cash conversion cycle absorbs much of the incremental profit. Operating margin has not recovered to the FY2022 peak, and the weak Q4 2025 raises questions about cost control at the busiest point of the year. Roughly a third of consolidated earnings belongs to minority shareholders in subsidiaries, and the founder family, together with a reciprocal-shareholding affiliate, controls 37% of the votes.
At KRW 3,430, the market values the company at about 0.5x book, under 3x EV/EBITDA and roughly 5x free cash flow, with a 3.6% dividend yield. Much of this discount is structural (illiquidity, family control, no coverage, budget dependency) rather than a mispricing of current earnings. A re-rating requires a visible catalyst: sustained margin expansion above 8%, a formal shareholder-return policy, treasury-share cancellation, or a simplification of the subsidiary structure. Absent these, DAIHAN is best viewed as a cash-rich, budget-cyclical income stock whose earnings are set to benefit from the 2026 R&D upcycle, with limited downside on asset value but uncertain upside on multiple.
Data limitations. DART primary documents could not be accessed directly; all DART-sourced figures were taken from aggregators (ETF Shopping, Valueline, Butler) that transcribe filings. The ISIN is derived from the KRX format and should be verified.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Ownership | Source |
|---|---|---|---|---|
Seo Hyun-jeong (서현정, Hyun Jeong Shu) | Representative Director (CEO) | Daughter of founder; special professor at Sangji University (appointed 2025); start date as CEO not disclosed in sources reviewed | 403,986 shares, 5.42% (Oct 2025) | S1; S4; S7 |
Seo Jeong-gu (서정구) | Founder; Group Chairman (대한과학그룹 회장) | Founded the business in 1980; former researcher at Korea Minting and Security Printing Corporation | 9.17% (FY2025) | S1; S5; S7 |
Seo Eun-taek (서은택) | Former CEO (c. 2012–2015) | Ex-Samsung Electronics; current role not confirmed | — | S5; S8 |
Lee Sang-beom (이상범) | CEO of a group affiliate | Listed among related parties | 0.95% | S1 |
“—” = not publicly disclosed.
Directors' Remuneration
| Metric | FY2025 | Source |
|---|---|---|
Average remuneration per director/auditor (KRW Mn) | 120 | S1 |
Number of directors/auditors in calculation | 5 | S1 |
Average employee salary (KRW Mn) | 49.39 | S1 |
Director-to-employee pay multiple (x) | 2.4 | S1 |
Major Shareholders
| Holder | Relationship | Stake (%) | Source / date |
|---|---|---|---|
Seo Jeong-gu | Largest shareholder (founder) | 9.17 | S1, 31 Dec 2025 |
(주)싸이랩코리아 (Sci-Lab Korea) | Affiliate (DAIHAN owns 37.78%) | 7.95 | S1, 31 Dec 2025 |
Seo Hyun-jeong | Child; CEO | 5.42 | S1; S4 |
Seo Kang-min | Sibling | 4.26 | S1 |
Lee Hyun-sook | Spouse | 3.45 | S1 |
Lee Jae-woong | Nephew | 3.06 | S1 |
Lee Sang-beom | Affiliate CEO | 0.95 | S1 |
Lee Jae-ho | Spouse's nephew | 0.83 | S1 |
Choi Yoon-kyung | Nephew's spouse | 0.83 | S1 |
Seo Kang-woon | Sibling | 0.36 | S1 |
Lee Choong-hyung | Son-in-law | 0.34 | S1 |
Seo Kyung-taek | Nephew | 0.34 | S1 |
Founder and related parties, total | — | 37.43 | S1 |
Minority shareholders (13,438 holders) | — | 62.64 | S1 |
Competitive Landscape
Competitors by Segment
| Business line | Competitor | Type | Positioning vs. DAIHAN | Source |
|---|---|---|---|---|
Lab-equipment distribution (Korea) | Seoulin Bioscience (KOSDAQ 038070) | Listed distributor (bio-research equipment, reagents; healthcare) | Similar scale (FY2025 revenue KRW 77.1 B) but far lower margin; more life-science/omics oriented | S14; S1 |
Lab-equipment distribution (Korea) | Avantor / VWR | Global distributor and manufacturer | Global scale, private-label and e-commerce; relaunching VWR brand in 2026 | S13 |
Lab-equipment distribution (Korea) | Thermo Fisher Scientific (Fisher Scientific channel) | Global leader | Dominant global scale; >12% global lab-equipment share | S12; S13 |
General lab instrument manufacturing (Korea) | JEIO Tech (제이오텍, Daejeon; private) | Domestic manufacturer of dryers, incubators, mixers, safety cabinets, reagent cabinets, medical refrigerators/freezers, chillers, reliability-test equipment | Closest domestic manufacturing rival; 2023 revenue KRW 57.7 B; ~295 employees | S14 |
General lab instrument manufacturing | Thermo Fisher (Heratherm, Forma, TSX freezers etc.) | Global | Premium brand in ovens, incubators, ULT freezers | S13 |
ULT and medical freezers | PHC (formerly Panasonic Healthcare), Eppendorf, Haier Biomedical, Thermo Fisher | Global | Global ULT freezer leaders | — |
Stirrers, shakers, homogenizers | IKA, Heidolph, Eppendorf | Global (German) | Premium mixing equipment | — |
Ovens and incubators | Memmert, Binder, Yamato Scientific | Global (German/Japanese) | Premium thermal equipment | — |
Biosafety cabinets and fume hoods | Esco, Labconco, Thermo Fisher | Global | Safety-cabinet specialists | — |
Analytical instruments (distribution) | Agilent, Danaher, Bruker, PerkinElmer (direct channels) | Global | Top-5 global lab-equipment players hold ~40% share | S12 |
Peer Comparison FY2025
| Metric | DAIHAN Scientific | Seoulin Bioscience | Thermo Fisher Scientific | Avantor |
|---|---|---|---|---|
Fiscal year | FY2025 | FY2025 | FY2025 | FY2025 |
Revenue | KRW 81.1 B | KRW 77.1 B | USD 44.56 B | USD 6.55 B |
Revenue growth | +13.1% | +2.2% | +4% (organic +2%) | −3.4% (organic −3%) |
Operating margin | 6.8% | 0.9% | 17.4% (GAAP) | Not computed; adj. EBITDA margin 16.3%; GAAP net loss USD 530 M |
R&D intensity | 1.4% | — | 3.1% (USD 1.40 B) | — |
Net income | KRW 4.8 B | KRW 0.6 B | — | −USD 530 M |
Source | S1; S2 | S14 | S13 | S13 |



